Publishing in The Lancet, the Newcastle kidney experts demonstrate that a new treatment called iptacopan, made by Novartis, prevents the complement system from damaging the kidneys. The treatment stops protein loss from the kidneys and stabilizes the kidney function.

The trial, with C3G patients from around the world, compared treatment with the drug Iptacopan to a placebo and demonstrated that it was both effective and safe.

What is C3G?

C3G—or Complement 3 glomerulopathy—happens when part of the immune system, called the complement system, over-reacts, resulting in damage to the body’s own kidneys, specifically tiny filters, called the glomeruli, which are responsible for filtering the blood of toxins and producing urine.